Year: 2024

The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R cHL, who have exhausted all standard of care treatments The combination showed a well-manageable safety profile with no unexpected safety signalsMANNHEIM, Germany, Dec. 08, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. The trial evaluates the safety and efficacy of the combination...

Media Release COPENHAGEN, Denmark; December 8, 2024Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following treatment with epcoritamab The data were selected as part of the 2024 American Society of Hematology’s (ASH’s) Annual Meeting Press Program in the Diagnosing and Treating Blood Cancers and “Almost Cancers” briefingGenmab A/S (Nasdaq: GMAB) today announced results from the Phase 1b/2 EPCORE® CLL-1 clinical trial evaluating epcoritamab (Abstract #883), a T-cell...

GUELPH, Ontario, Dec. 08, 2024 (GLOBE NEWSWIRE) — Current Water Technologies Inc. (TSX-V: WATR) (“CWTI” or “the Company” or “the Corporation“), announces that due to the ongoing postal strike in Canada, the Company’s annual meeting materials are being delayed. The Company’s Meeting materials may be viewed on the Company’s SEDAR+ corporate website at www.sedarplus.ca and are also available electronically at https://docs.tsxtrust.com/2198. Registered shareholders requesting a proxy for the meeting may contact TSX Trust Company at 1-866- 600-5869 or email tsxtis@tmx.com. Proxies, completed and signed, should be forwarded by deadline, 10:00 a.m. EST, Wednesday, December 18, 2024. Beneficial holders, who hold their shares through a broker, and have not received their information...

Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab Five patients receiving ravulizumab did not achieve meaningful LDH control compared to one patient receiving poze-cemdi; after switching to the combination, four of the five previously treated with ravulizumab achieved LDH control A separate registrational cohort is ongoing, investigating poze-cemdi against eculizumab TARRYTOWN, N.Y., Dec. 07, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi)...

Media Release COPENHAGEN, Denmark; December 7, 2024Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma (FL) following treatment with epcoritamab plus lenalidomide + rituximab (R2) Long-term follow-up results demonstrated strong and durable efficacy, with an estimated two-year overall survival (OS) rate of 90 percent Results follow recent breakthrough therapy designation (BTD) granted by U.S. Food and Drug Administration (FDA) and support ongoing Phase 3 EPCORE® FL-1 trial evaluating epcoritamab + R2 in patients with R/R FLGenmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial evaluating fixed-duration epcoritamab, a T-cell engaging bispecific...

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of treatment responses SEATTLE, Dec. 07, 2024 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data demonstrating the impact of measurable residual disease (MRD) assessment using Adaptive’s next-generation sequencing-based clonoSEQ® test in blood cancer clinical care and drug development. The data are featured in more than 65 abstracts being presented at the 66th Annual Meeting of the American Society of Hematology (ASH), taking place...

NEWPORT NEWS, Va., Dec. 07, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) today christened Virginia-class submarine Arkansas (SSN 800) at the company’s Newport News Shipbuilding (NNS) division. “Today we celebrate the mighty submarine Arkansas, and we honor bravery and impact: the heroes and heroic moments that shape our future and make us who we are,” NNS President Jennifer Boykin said. “As high school students, the Little Rock Nine exhibited courage, and showed the American people what determination and perseverance look like. Their spirit guided them then, and today SSN 800 will be instilled with this same spirit of courage, determination, and resilience.” The ship’s sponsors are the six women of the historic group known as the Little Rock Nine, the first African American students to attend all-white Central High School in Little...

Admirals Group AS has entered into an agreement to sell its wholly owned subsidiary, Admirals AU PTY Ltd (Australia), a licensed investment company, to a non-related party, as part of the Admirals group’s ongoing optimization of its geographic focus. The transaction, subject to customary closing conditions, is expected to positively contribute to Admirals Group AS’s net profit and streamline its operations in alignment with its core strategy. This strategic move underscores Admirals Group AS’s commitment to delivering value by concentrating resources in key regions where it sees the strongest potential for growth and operational efficiency. Additional information:  Alexander Tsikhilov Chairman of the Management Board of Admirals Group AS alexander.tsikhilov@admirals.com  +372 6309 300 https://www.admirals.group/

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied. 96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy. These data reinforce the potential of Galapagos’ decentralized cell therapy manufacturing platform to deliver fresh, fit cells, fast, driving positive patient outcomes.Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American...

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California. A poster titled “CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma” characterizes the selective binding of CD38-SADA to DOTA-chelated lanthanide metals and high-avidity binding...